AcelRx Pharmaceuticals Inc. (ACRX)

3.22
0.06 1.90
NASDAQ : Health Technology
Prev Close 3.16
Open 3.21
Day Low/High 3.07 / 3.30
52 Wk Low/High 1.65 / 5.05
Volume 1.70M
Avg Volume 2.28M
Exchange NASDAQ
Shares Outstanding 78.76M
Market Cap 255.96M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

It was a busy week of moves in the portfolio as we head into the latter half of the second quarter.

Adding a Specialty Pharma Name

AcelRx Pharmaceuticals is another interesting, yet speculative, play.

ACRX: Insiders vs. Shorts

ACRX: Insiders vs. Shorts

The most recent short interest data was recently released for the 09/30/2016 settlement date, and AcelRx Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.72 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

AcelRx Pharmaceuticals (ACRX) announced on Thursday that ARX-04, its experimental pain relief drug, had positive results in a phase III clinical trial.

First Week of ACRX September 16th Options Trading

First Week of ACRX September 16th Options Trading

Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume

AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a weak on high relative volume candidate

AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today

AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today

Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate

Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters

Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters

There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

10 Worst Biotech Stocks in the NASDAQ

10 Worst Biotech Stocks in the NASDAQ

Some biotech stocks way underperformed in this red-hot sector.

Insider Trading Alert - LAD, RSE And ACRX Traded By Insiders

Insider Trading Alert - LAD, RSE And ACRX Traded By Insiders

Stocks with insider trader activity include LAD, RSE and ACRX

Insider Trading Alert - STFC, ACRX And CSC Traded By Insiders

Insider Trading Alert - STFC, ACRX And CSC Traded By Insiders

Stocks with insider trader activity include STFC, ACRX and CSC

AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?

AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?

AcelRx shareholders were burned yet again when the company announced new clinical trials were required for its flagship drug. What's to come for this struggling biotech company?

AcelRx Pharmaceuticals (ACRX) Stock Extends Losses Today as Jefferies Downgrades

AcelRx Pharmaceuticals (ACRX) Stock Extends Losses Today as Jefferies Downgrades

Shares of AcelRx Pharmaceuticals (ACRX) are extending losses as Jefferies downgraded the company to 'hold' from 'buy.'

AcelRx Pharmaceuticals (ACRX) Stock Tanks Today on FDA Demand For Further Zalviso Trials

AcelRx Pharmaceuticals (ACRX) Stock Tanks Today on FDA Demand For Further Zalviso Trials

AcelRx Pharmaceuticals (ACRX) shares are down over 30% after the company announced a delay to the resubmitting of Zalviso's regulatory application due to increased FDA scrutiny.

AcelRx Pharmaceuticals is Now Oversold (ACRX)

AcelRx Pharmaceuticals is Now Oversold (ACRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?

Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?

AcelRx Pharmaceuticals was hit with an FDA rejection and is due to resubmit their drug this quarter; should investors stay away or is there an opportunity to be had?

5 Stocks Under $10 Setting Up to Trade Higher: Callon Petroleum and More

5 Stocks Under $10 Setting Up to Trade Higher: Callon Petroleum and More

These setups often produce monster moves higher in very short time frames.

AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell

AcelRx Pharmaceuticals (ACRX) Downgraded From Hold to Sell

AcelRx Pharmaceuticals (ACRX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CLMS, FCCY, FCS Downgrades: ACRX, MWE, QIHU, RAIL, SBR, TIVO, UCP Initiations: CBMG Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on...

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against AcelRx Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 1, 2014

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against AcelRx Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 1, 2014

Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold

AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold

AcelRx Pharmaceuticals (ACRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.

AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report

AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report

Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACRX, ADT, CMGE, DMRC, FCN, FFBC, GVA, ORBC, PMC, SPOK, TCPC Downgrades: ATVI, BRKR, ICPT, LBIX, LUK, MPAA, PEGA, PHI, RIG Initiations: AAOI, AR, CXP, LDRH, QTS, SFXE, SGM, WNRL, XLRN Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on...

AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action...

TheStreet Quant Rating: D- (Sell)